doi: 10.1161/hy0202.103297
(Hypertension. 2002;39:418.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
Role of Methoxyestradiols in the Growth Inhibitory Effects of Estradiol on Human Glomerular Mesangial Cells
From the Center for Clinical Pharmacology, Departments of Medicine (R.G.D., D.G.G., C.Z., E.K.J.), and Pharmacology (C.Z., E.K.J.), University of Pittsburgh Medical Center, Pittsburgh; and Clinic for Endocrinology Department of Obstetrics and Gynecology, University Hospital Zurich (R.K.D., P.J.K., B.I.), Zurich, Switzerland.
Correspondence to Dr Raghvendra K. Dubey, D217, NORD-1, Clinic for Endocrinology, Department of Obstetrics and Gynecology, Frauenklinik, Zurich 8091, Switzerland. E-mail rag{at}fhk.usz.ch
Metabolism of locally applied 17ß-estradiol (estradiol) to methoxyestradiols contributes to the growth inhibiting effects of estradiol on vascular smooth muscle cells via an estrogen receptor (ER)-independent mechanism. Because vascular smooth muscle cells are phenotypically similar to glomerular mesangial cells, it is feasible that estradiol inhibits glomerular mesangial cell growth via a similar mechanism, and this possibility was investigated. In human glomerular mesangail cells, estradiol concentration dependently (1 to 100 nmol/L) inhibited serum-induced proliferation (cell number) and DNA (3[H]-thymidine incorporation) and collagen (3[H]-proline incorporation) synthesis. The inhibitory effects of estradiol were mimicked by 2-hydroxyestradiol and 2-methoxyestradiol, metabolites of estradiol with little affinity for ERs. 2-Hydroxyestradiol and 2-methoxyestradiol were more potent growth inhibitors than estradiol. The inhibitory effects of estradiol were enhanced by CYP450 inducers 3-methylcholanthrene (10 µmol/L) and phenobarbital (10 µmol/L) and blocked by the CYP450 inhibitor 1-aminobenzotriazole (10 µmol/L). The growth inhibitory effects of estradiol were also blocked by quercetin (10 µmol/L) and OR 486 (10 µmol/L) inhibitors of catechol-O-methyltransferase (converts catecholestradiols to methoxyestradiols). ICI182780 (ER antagonist with ER binding affinity similar to estradiol) blocked the growth inhibitory effects of estradiol (1 to 100 nmol/L) only at concentrations (>50 µmol/L) that inhibited estradiol metabolism to catecholestradiols. The growth inhibitory effects of 2-hydroxyestradiol were abrogated by quercetin and OR486 (two structurally dissimilar catechol-O-methyltransferase inhibitors), but not by ICI182780. However, the growth inhibitory effects of 2-methoxyestradiol were unaltered by catechol-O-methyltransferase inhibitors and ICI182780. In conclusion, our findings provide the first evidence that methoxyestradiols mediate the growth inhibitory effects of locally applied estradiol on glomerular mesangial cell growth via an ER-independent mechanism.
Key Words: metabolism • estrogen • renal disease • glomerulosclerosis • mesangium • menopause
This article has been cited by other articles:
 |
|
 |
|
  I. Z. A. Pawluczyk, E. K. C. Tan, and K. P. G. Harris Rat mesangial cells exhibit sex-specific profibrotic and proinflammatory phenotypes Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1753 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Dragun and A. Haase-Fielitz Low catechol-O-methyltransferase and 2-methoxyestradiol in preeclampsia: more than a unifying hypothesis Nephrol. Dial. Transplant., January 1, 2009; 24(1): 31 - 33. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Csete Gender Issues in Transplantation Anesth. Analg., July 1, 2008; 107(1): 232 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Baylis Sexual Dimorphism of the Aging Kidney: Role of Nitric Oxide Deficiency Physiology, June 1, 2008; 23(3): 142 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Mankhey, C. C. Wells, F. Bhatti, and C. Maric 17beta-Estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R769 - R777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. B. Berg Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2577 - 2582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Karl, M. Berho, J. Pignac-Kobinger, G. E. Striker, and S. J. Elliot Differential Effects of Continuous and Intermittent 17{beta}-Estradiol Replacement and Tamoxifen Therapy on the Prevention of Glomerulosclerosis: Modulation of the Mesangial Cell Phenotype in Vivo Am. J. Pathol., August 1, 2006; 169(2): 351 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Masi, L. C. Hawkley, J. D. Berry, and J. T. Cacioppo Estrogen Metabolites and Systolic Blood Pressure in a Population-Based Sample of Postmenopausal Women J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1015 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kisselev, W.-H. Schunck, I. Roots, and D. Schwarz Association of CYP1A1 Polymorphisms with Differential Metabolic Activation of 17{beta}-Estradiol and Estrone Cancer Res., April 1, 2005; 65(7): 2972 - 2978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Mankhey, F. Bhatti, and C. Maric 17{beta}-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy Am J Physiol Renal Physiol, February 1, 2005; 288(2): F399 - F405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Dubey, B. Imthurn, L. C. Zacharia, and E. K. Jackson Hormone Replacement Therapy and Cardiovascular Disease: What Went Wrong and Where Do We Go From Here? Hypertension, December 1, 2004; 44(6): 789 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Lane, J. Sun, K. Devish, and W. J. Langer Dissociation of renal TGF-{beta} and hypertrophy in female rats with diabetes mellitus Am J Physiol Renal Physiol, November 1, 2004; 287(5): F1011 - F1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Dubey, E. K. Jackson, D. G. Gillespie, L. C. Zacharia, and B. Imthurn Catecholamines Block the Antimitogenic Effect of Estradiol on Human Coronary Artery Smooth Muscle Cells J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3922 - 3931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Maric, K. Sandberg, and C. Hinojosa-Laborde Glomerulosclerosis and Tubulointerstitial Fibrosis are Attenuated with 17{beta}-Estradiol in the Aging Dahl Salt Sensitive Rat J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1546 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Zacharia, C. A. Piche, R. M. Fielding, K. M. Holland, S. D. Allison, R. K. Dubey, and E. K. Jackson 2-Hydroxyestradiol Is a Prodrug of 2-Methoxyestradiol J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1093 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Dubey, S. P. Tofovic, and E. K. Jackson Cardiovascular Pharmacology of Estradiol Metabolites J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 403 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Zacharia, J. A. Gogos, M. Karayiorgou, E. K. Jackson, D. G. Gillespie, F. Barchiesi, and R. K. Dubey Methoxyestradiols Mediate the Antimitogenic Effects of 17{beta}-Estradiol: Direct Evidence From Catechol-O-Methyltransferase-Knockout Mice Circulation, December 16, 2003; 108(24): 2974 - 2978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Dubey, L. C. Zacharia, D. G. Gillespie, B. Imthurn, and E. K. Jackson Catecholamines Block the Antimitogenic Effect of Estradiol on Human Glomerular Mesangial Cells Hypertension, September 1, 2003; 42(3): 349 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Zacharia, R. K. Dubey, Z. Mi, and E. K. Jackson Methylation of 2-Hydroxyestradiol in Isolated Organs Hypertension, July 1, 2003; 42(1): 82 - 87. [Abstract] [Full Text] [PDF]
|
|